Brought to you by 
Celgene licenses Thalomid to Pharmion
06 Dec 2004
Executive Summary
Celgene (small-molecule drugs for cancer and immunological diseases) has licensed Thalomid (thalidomide) to Pharmion (focuses on hematology and oncology therapeutics) to treat cancer and inflammatory diseases in foreign markets excluding Canada, China, Japan, Taiwan, and Korea.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com